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Abstract: Pancreatic cancer (PanCa) is one of the leading causes of death from cancer in the United
States. The current standard treatment for pancreatic cancer is gemcitabine, but its success is poor
due to the emergence of drug resistance. Natural products have been widely investigated as potential
candidates in cancer therapies, and cucurbitacin D (Cuc D) has shown excellent anticancer properties
in various models. However, there is no report on the therapeutic effect of Cuc D in PanCa. In
the present study, we investigated the effects of the Cuc D on PanCa cells in vitro and in vivo.
Cuc D inhibited the viability of PanCa cells in a dose and time dependent manner, as evident by
MTS assays. Furthermore, Cuc D treatment suppressed the colony formation, arrest cell cycle, and
decreased the invasion and migration of PanCa cells. Notably, our findings suggest that mucin 13
(MUC13) is down-regulated upon Cuc D treatment, as demonstrated by Western blot and qPCR
analyses. Furthermore, we report that the treatment with Cuc D restores miR-145 expression in
PanCa cells/tissues. Cuc D treatment suppresses the proliferation of gemcitabine resistant PanCa
cells and inhibits RRM1/2 expression. Treatment with Cuc D effectively inhibited the growth of
xenograft tumors. Taken together, Cuc D could be utilized as a novel therapeutic agents for the
treatment/sensitization of PanCa.
Keywords: pancreatic cancer; cucurbitacin D; mucin; miR-145 and MUC13
1. Introduction
Pancreatic cancer (PanCa) represents one of the most common aggressive solid malignancies
and it is fourth leading cause of cancer-related deaths in the Unites States [1]. Poor prognosis, worst
outcomes, and short survival are hallmarks of this cancer. Although our understanding of its etiology
has increased over the past few decades, this has not resulted in a significant improvement in treatment
options. Pancreatic cancer patients currently have a low survival of around eight months and ~8%
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five-year survival rate. PanCa is estimated to be the second leading cause of cancer deaths in the
United States by 2030 [2]. Recently, gemcitabine (GEM), which is a nucleoside analog, has become
an FDA-approved treatment, but, in most cases, it can only prolong survival by a few weeks [3].
Recently used combination therapies, such as FOLFIRINOX and gemcitabine/Abraxane, have shown
improved efficacy, but it can cause profound toxicity [4]. Unfortunately, there are currently no curative
options for advanced or metastatic PanCa [5]. The inherent resistance of PanCa to available treatment
options poses a major challenge in reducing the mortality from this pernicious disease. The proper
management of PanCa requires the development of incipient targeted therapies with less toxicity and
a correspondingly improved efficacy.
Nowadays, natural products are of significant interest as new drug sources for cancer therapy [6].
Recently, natural bioactive agents have been shown a number of therapeutic activities including
anti-cancerous properties, but inadequate bioavailability restricts their clinical use [7–10]. The
cucurbitacins are oxygenated tetracyclic triterpenoids that are isolated from the Cucurbitaceae family
and are well known for the acridness of edible products, like pumpkins, gourds, and squashes. They
are known to exhibit potent anti-inflammatory and anti-cancer effects on various tumors [11]. Several
analogues, including (B, D, E, I, F, O, P, and Q), have been shown to suppress tumor cell proliferation via
the inhibition of STAT3 phosphorylation [12]. Although cucurbitacins have moderate to high toxicity,
their structural properties may contribute to potential future chemotherapeutic modalities. Notably,
Ding et al. (2010) observed that cucurbitacin D analogue (Cuc D) is non-toxic in peripheral blood
mononuclear cells from healthy donors or in mouse primary cells [13]. Several reports have shown
the anticancer activity of Cuc D in various cancer models [13–15]. Previously, we have shown the
anticancer activity of Cuc D in cervical and prostate cancer [16,17]. Cuc D has been reported to inhibit
the proliferation of doxorubicin-resistant human breast carcinoma cells [15]. In human T cell leukemia,
Cuc D induce growth suppression via the inhibition of proteasome pathways [13]. Additionally, Cuc
D has been shown to downregulate the heat shock protein 90 (HSP90) chaperone machinery [18].
However, the exact molecular mechanism of its action needs to be elucidated.
In the present study, we investigated whether the Cuc D could inhibit proliferation, migration,
invasion, and arrest cell cycle in PanCa cells. The results of our study revealed that Cuc D significantly
downregulated the Mucin 13 (MUC13) expression in PanCa in vitro and in vivo. MUC13 is aberrantly
overexpressed in PanCa and the ectopic expression of MUC13 augments tumorigenic features, such
as enhanced cell proliferation, cell motility, cell invasion, and in vivo tumor growth [19]. We have
previously shown that miR-145 expression inversely correlates with MUC13 expression in PanCa
cells and human tumor tissues [20]. These small non-coding RNAs function by selectively binding to
complementary 3′ UTR regions of mRNAs, resulting in target mRNA degradation or the inhibition
of mRNA translation. Our findings further report that Cuc D mediated downregulation is due to
the partial restoration of miR-145 in PanCa. Additionally, Cuc D treatment suppresses the growth of
gemcitabine resistant PanCa and inhibits the expression of ribonucleotide reductase (RRM1/2), key
regulator proteins involved in chemo-resistance. Overall, our study is the first to suggest a potential
role for Cuc D in the PanCa therapy.
2. Materials and Methods
2.1. Cell Culture
Human pancreatic cancer cell lines (AsPC-1, BxPC-3, CaPan-1, and HPAF-II) were purchased from
American Type Culture Collection (Manassas, VA, USA). AsPC-1, BxPC-3, and CaPan-1 were cultured
as monolayer in RPMI1640, while HPAF-II was grown in DMEM/F-12 media (HyClone Laboratories,
Inc., South Logan, UT, USA). The media used were supplemented with 10% heat-inactivated FBS
(Atlanta Biologicals, Atlanta, GA, USA), 1% antibiotic/antimycotic and cells were incubated at 37 ◦C
in a humidified atmosphere (5% CO2 and 95% air atmosphere). DMSO was used as vehicle control
throughout the study.
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2.2. Cell Proliferation Assay
MTS assay was performed to study the anti-proliferative activity of the Cuc D as described
previously [20]. Briefly, the cells were seeded in 96-well plates at a density of 2.5 × 103 cells per well
and allowed to stand overnight at 37 ◦C and 5% CO2 in the incubator. Next day, the cells were treated
with different concentrations of Cuc D (0.1, 0.25, and 0.5 µM). DMSO was used as a vehicle control. At
the time interval of 24, 48, 72 and 96 h, 25 µL of MTS reagent was added and absorbance was then taken
at 490 nm after 2 h using SpectraMax plus 384 spectrophotometers, (Molecular Devices, Sunnyvale,
CA, USA). The experiment was conducted in quadruplicates. The data were analyzed with respect to
the vehicle control.
2.3. Colony Formation Assay
Colony formation assay was performed to investigate the long-term effect of Cuc D on the
clonogenic potential of AsPC-1, BxPC-3, CaPan-1, and HPAF-II cells. Briefly, in a six-well plate, 500
cells were seeded per well and then allowed to grow for three days. The cells were then treated for
seven days with Cuc D at different concentrations (25, 50, 100 nM). DMSO was used as vehicle control.
After seven days, the media was replaced with respective growth medium for another one week. After
this, the cell colonies were fixed in methanol and then stained in hematoxylin. The colonies were
counted and then percentage viability was calculated with respect to the vehicle.
2.4. Cell Cycle Analysis
Approximately 70% confluent HPAF-II cells were treated with Cuc D (0.5 and 1 µM) for 24 h. The
cells were trypsinized and then washed twice with ice cold PBS (1×). The cell pellet was resuspended
in 50µL ice cold PBS (1×) and 450µL cold methanol and left for 1 h at 4 ◦C. The cells were washed
twice with ice cold PBS (1×), suspended in 500µL PBS, and then incubated with 5µL RNase (20µg/mL
final concentration) at 37 ◦C for 1 h. The cells were chilled over ice for 10 min and then stained with
propidium iodide (50µg/mL final concentration for 1 h). The stained cells were further analyzed by
flow cytometry (BD Accuri C6; Becton-Dickinson, Mountain View, CA, USA).
2.5. Migration Assay
Cell migration was carried out as per the instructions of the manufacturer in Corning’s 96-well
HTS trans-well. PanCa cells (AsPC-1 and HPAF-II) were seeded at a density of 50,000 cell/well in the
upper chamber of the plate containing serum-free culture medium and then treated with Cuc D for
18 h, following which cells were allowed to migrate to lower chamber containing 10% FBS. After the
completion of time, the cells in the upper chamber were completely removed by cotton swab, and
the cells in the lower chamber were fixed in 4% paraformaldehyde solution. These cells were further
stained with crystal violet. A phase contrast microscope was used to observe the migrated cells.
2.6. Agarose Bead Assay
Agarose bead assay was also used to study cell migration, as previously described [19]. Briefly, the
cells were mixed into a low melting point agarose solution and suspension drops were placed on plates.
The cells were treated for 48 h with Cuc D and photographed while using a phase-contrast microscope.
2.7. Wound Healing Assay
PanCa cell migration was assessed by an in vitro wound healing assay as previously described [16].
Briefly, the cells were densely plated on a six-well tissue culture plate. A standardized wound was
made while using a plastic tip of P200, followed by treatment with Cuc D (0.1 and 0.5 µM).
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2.8. Invasion Assay
Biocoat Matrigel Invasion Chambers (BD Biosciences, San Jose, CA, USA) were used to investigate
the effect of Cuc D on the invasiveness of PanCa cells as described previously [16]. The invading cells
were fixed with methanol after 48 h incubation and then stained with crystal violet. The invaded cells
were counted and then plotted as a percentage invasion of the cells treated with Cuc D as compared to
the control.
2.9. Western Blotting
To determine the effect of Cuc D on expression in PanCa, Western blot analysis was performed.
Protein lysates were prepared as previously described [20]. The proteins were analyzed by
immunoblotting with anti-MUC13 Mab (clone PPZ020) and anti-β–Actin (Sigma, St. Louis, MO, USA).
2.10. Transfection and Quantitative Real-Time Polymerase
The cells were transfected using Lipofectamine 2000 (Invitrogen, Life Technologies, Grand Island,
NY, USA) as per the manufacture’s protocol. Briefly, total RNA was isolated from control and Cuc D
treated PanCa cells while using TRIzol™ reagent (Invitrogen, Life Technologies, Grand Island, NY,
USA). 100 ng total RNA was reverse transcribed into cDNA while using specific primers that were
designed for miRNA analysis (Applied Biosystems, Foster City, CA, USA) using High Capacity cDNA
Reverse Transcription kit (Applied Biosystems, Foster City, CA). The mRNA expression of target genes
(MUC13, RRM1 and RRM2) was analyzed by real-time PCR and semi-quantitative PCR was performed
to assess the MUC13 mRNA level by using standard three step procedure as previously described [20].
The expression of MUC13 was normalized to GAPDH. The expression of miR-145 was normalized
with the expression of control U6B small nuclear RNA (RNU6B).
2.11. Molecular Docking
Molecular docking was carried out while using Autodock Vina and AutoDock 4 package, as
described previously [21,22]. Autodock Vina uses an advanced docking algorithm and scoring function
of protein ligand interactions. As there is no MUC13 structure related information available, the selected
sequence of MUC13 was modelled to generate the three-dimensional model while using I-TASSER
and SWISS-MODEL server [23,24]. The SWISS-MODEL methodology includes general steps of BlastP
for selected MUC13 sequence against Protein Data Base to find a suitable template. Transmembrane
protease from Mus musculus (PDBID 2E7V) was selected as the best suitable templates and using these
templates generated the homology model of MUC13. The best conformation of modelled MUC13, as
predicted by SWISS-MODEL, was further validated using Ramachandran plot [25]. The conformation
of the predicted model was calculated by analyzing the phi (Φ) and psi (Ψ) torsion angles while
using MolProbity online server. Prior to docking analysis, the structure was amended by take out the
ligand and co-crystallized water molecules, followed by the addition of polar hydrogens and Gasteiger
charges while using Auto Dock Tool (ADT). The two-dimensional (2D) and three-dimensional (3D)
structures of Cuc D were generated and energy as minimized while using ChemBio3D Ultra 12.0. The
protein receptor molecules and ligand were converted to the appropriate docking format through
PyRx. Subsequent to the preparation of coordinate files, the ligand was docked by defining a grid box
around the protein active site and bound conformations, binding affinity, and possible protein-ligand
interactions were studied. PyMOL viewer (Schrödinger, LLC) and “Receptor-Ligand Interactions”
modules of BIOVIA/Discovery Studio 2017R2 were used for the visualization and structure analysis of
the docked complexes and for generating two/three dimensional images for the analysis of hydrogen
bonds and hydrophobic interactions.
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2.12. Xenograft Study
We performed ectopic xenograft studies in mice to determine the anti-tumor effect of Cuc D. To this
end, six-week old NOD-SCID gamma mice were purchased from Jackson laboratory and maintained
in a pathogen-free environment. All of the procedures were carried out in accordance with the protocol
that the UTHSC Institutional Animal Care and Use Committee (UTHSC-IACUC) approved. HPAF-II
cells (4 × 106 cells) were suspended in phosphate buffer saline (PBS) and Matrigel (BD Biosciences)
solution (1:1 ratio) and subcutaneously injected on the dorsal flanks of each mouse to establish ectopic
xenograft tumors in mice. Mice tumor growth was monitored while using a digital Vernier caliper.
When tumor volume reached ~100 mm3, mice were divided into control groups and Cuc D treatment
groups. The mice were treated with Cuc D (1 mg/kg bwt thrice a week; intra-peritoneally) or vehicle
control (PBS). Tumor volumes were measured weekly and then calculated while using formula 0.5238
× L ×W ×H, where L is length, W is width, and H is tumor height. Mice were euthanized when the
control mice tumor volume reached ~1000 mm3. The tumors were excised and processed for RNA,
tissue lysates, histopathology, and preparation of slides (5µm section) at the time of sacrifice.
2.13. Immunohistochemistry (IHC)
IHC analysis for PCNA and MUC13 proteins was performed on formalin-fixed, paraffin-embedded
xenograft tumors (5-micron sections) as described previously [20]. Briefly, the tumor tissues were
deparaffinized, rehydrated, treated with 0.3 percent hydrogen peroxide, and then processed for antigen
retrieval while using a heat-induced technique. The samples were processed for staining with PCNA
and MUC13 antibodies after blocking with background sniper (BioCare Medical, Concord, CA, USA).
The expression of these proteins was detected while using a MACH 4 Universal HRP Polymer Detection
Kit (BioCare Medical) and 3,9-diaminobenzidine (DAB Substrate Kit, Vector Laboratories, Burlingame,
CA, USA). The slides were counter-stained with hematoxylin, dehydrated, mounted with VectaMount
(Vector Laboratories), and visualized using an Olympus BX 41 microscope (Olympus Corporation,
Tokyo, Japan).
2.14. In Situ Hybridization
In situ hybridization technique was used in order to detect the expression of miR-145 in tissues
of control and treated xenograft mice by Biochain kit (Catalog number K2191050; Biochain IsHyb In
Situ hybridization kit) as described previously [20]. Briefly, the tissues were deparaffinized and then
fixed in 4% paraformaldehyde in DEPC-PBS for 20 min. They were digested using 2x standard saline
citrate and 0.1% Triton-X for next 25 min. The tissue was prehybridized with prehybridization solution
provided with the kit for 4 h at 48 ◦C. This followed the hybridization of the slides with hybridization
buffer and digoxigenin labelled probe (EXIQON, Woburm, MA, USA) at 45 ◦C overnight. The slides
were blocked using 1x blocking solution that was provided with the kit after stringent washing of
tissue slides with various grades of standard saline citrate. This followed the subsequent incubation of
tissues overnight with the AP-conjugated anti-digoxigenin antibody. Further, the slides were washed
for 5 min. with 1x Alkaline Phosphatase buffer twice.
2.15. Bioavailability Studies of Cuc D
Cuc D (2mg/kg) was given orally and intra-peritoneally. A 150 µL blood sample was withdrawn
from retroorbital vein at 30 min., 12 h, and 48 h. 100 µL of methanol were added to the plasma samples
and then mixed by vortexing. The mixture was centrifuged at 1500 rcf for 5 min. Cuc D concentration
was achieved while using HPLC Dynamax liquid chromatography (Varian chromatography systems)
equipped with PDA-2 (photodiode array UV detector) and Altima C-18 (Alltech analytical column,
5 µm, length 250 mm, ID 4.6 mm), which is developed with the gradient solvent system of MeOH/H2O
and flow rate of 1 mL/min. Cuc B was used as an internal standard.
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2.16. Statistical Analysis
Statistical analysis was performed while using an unpaired two-tailed Student t-test and it was
employed to assess the statistical significance between the control and Cuc D-treated groups. p values
< 0.05 were considered to be significant (* p < 0.05, ** p < 0.01, *** p < 0.001).
3. Results
3.1. Cuc D Treatment Suppresses Proliferation and Clonogenicity of Pancreatic Cancer Cells
In this study, we investigated the anti-proliferative activity of Cuc D against pancreatic cancer cells.
The anti-proliferative effects of serial concentrations of Cuc D (for 24–96 h treatment) on pancreatic
cancer cells were examined while using MTS assay (Figure 1A(i–iv)). Cuc D treatment caused a dose
(0.1 to 0.5µM) and time dependent decrease in viability of AsPC-1, BxPC3, CaPan-1, and HPAF-II cells.
In addition, colony formation assays were performed to assess the long-term effect of Cuc D. Treatment
with Cuc D was shown to significantly inhibit colony formation when compared to the control cells in
a dose-dependent manner (p < 0.05, Figure 1B,C). These results demonstrated that Cuc D efficiently
inhibited the growth and clonogenicity of pancreatic cancer cells. The Cuc D effects were very similar
in all four pancreatic cancer cell lines (AsPC-1, BxPC-3, CaPan-1, and HPAF-II) tested. Therefore, we
selected AsPC-1 and HPAF-II cell lines for further studies.
3.2. Cuc D Treatment Effectively Arrests Cell Cycle in G2/M Phase
Cancer progression is associated with the aberrant regulation of the cell cycle [26]. Thus, using
PanCa cells, we investigated the effect of Cuc D on the cell cycle through flow cytometry. Cuc D caused
a dose dependent growth arrest in the G2/M phase of the cell cycle (Figure 2A(i,ii); representative data
for HPAF-II shown). The percentage of cells in the G2/M phase increased after 24 h of drug treatment
as compared to the vehicle control group, as shown in Figure 2A.
3.3. Cuc D Treatment Inhibited Migratory Potential of PanCa Cells
The migration of epithelial cells is an important step in cancer metastasis [27]. Therefore, treatment
designed to inhibit the ability of tumor cells to migrate can have a dramatic improvement in the
survival of cancer patients. We therefore wanted to determine whether Cuc D could inhibit PanCa
cell migratory properties through Boyden chamber assay, agarose bead assay, and wound healing
assay. Treatment with Cuc D showed that fewer cells migrated through the semipermeable layer
when compared to control (Figure 2B(i,ii)). The PanCa cells were trapped in the agarose beads and
treated with Cuc D for 48 h, which then showed a smaller number of migratory cells from the bead
compared to the control. (Figure 2C). Similar observations were also observed in a wound healing
assay following Cuc D treatment, as there was a marked decrease in cell migration in the wound that
was prepared by using 200 µL pipette tip (Figure 2D). Overall, these results confirm that Cuc D has an
effective anti-migration capability against PanCa cells.
Cells 2020, 9, 103 7 of 17
Cells 2019, 8, x 6 of 17 
 
3.1. Cuc D Treatment Suppresses Proliferation and Clonogenicity of Pancreatic Cancer Cells 
In this study, we investigated the anti-proliferative activity of Cuc D against pancreatic cancer 
cells. The anti-proliferative effects of serial concentrations of Cuc D (for 24–96 h treatment) on 
pancreatic cancer cells were examined while using MTS assay (Figure 1 Ai–iv). Cuc D treatment 
caused a dose (0.1 to 0.5µM) and time dependent decrease in viability of AsPC-1, BxPC3, CaPan-1, 
and HPAF-II cells. In addition, colony formation assays were performed to assess the long-term effect 
of Cuc D. Treatment with Cuc D was shown to significantly inhibit colony formation when compared 
to the control cells in a dose-dependent manner (p < 0.05, Figure 1B,C). These results demonstrated 
that Cuc D efficiently inhibited the growth and clonogenicity of pancreatic cancer cells. The Cuc D 
effects were very similar in all four pancreatic cancer cell lines (AsPC-1, BxPC-3, CaPan-1, and HPAF-
II) tested. Therefore, we selected AsPC-1 and HPAF-II cell lines for further studies. 
 
Figure 1. Cuc D decreases proliferation and colony formation of pancreatic cancer cells. (A) Cuc D 
decreases the proliferation of AsPC-1, BxPC-3, CaPan-1, and HPAF-II cells (Ai–iv). Briefly, PanCa 
(2500) cells were seeded in each well of 96-well plate and after overnight incubation; cells were treated 
with indicated concentrations of Cuc D for 24, 48, 72, and 96 h. Cell viability was assessed by MTS 
Figure 1. Cuc D decreases proliferation and colony formation of pancreatic cancer cells. (A) Cuc D
decreases the proliferation of AsPC-1, BxPC-3, CaPan-1, and HPAF-II cells (Ai–Aiv). Briefly, PanCa
(2500) cells were seeded in each well of 96-well plate and after overnight incubation; cells were treated
with indicated concentrations of Cuc D for 24, 48, 72, and 96 h. Cell viability was assessed by MTS assay.
The graph represents the percent viable cells compared to the vehicle-treated cells. Each concentration
value shown in bar graph is the mean ± SE of quadruplicates wells of each group. (B) Cuc D inhibits
colony formation ability of PanCa cells (B,C). In brief, 500 cells were seeded in each well of 6-well plates.
After three days, the cells were treated with indicated concentrations of Cuc D and colonies obtained
were stained with hematoxylin. Photographs were taken by UVP-gel documentation system for all
cells. Bar graphs represent number of percentage of colonies formed with respect to vehicle control in
each group. The experiments were performed in triplicate. Asterisk (*) denotes the significant value
p < 0.05 when applied student’s t-test, and two asterisks (**) indicates as significance of p < 0.01.
Cells 2020, 9, 103 8 of 17
Cells 2019, 8, x 7 of 17 
 
assay. The graph represents the percent viable cells compared to the vehicle-treated cells. Each 
concentration value shown in bar graph is the mean ± SE of quadruplicates wells of each group. (B) 
Cuc D inhibits colony formation ability of PanCa cells (B,C). In brief, 500 cells were seeded in each 
well of 6-well plates. After three days, the cells were treated with indicated concentrations of Cuc D 
and colonies obtained were stained with hematoxylin. Photographs were taken by UVP-gel 
documentation system for all cells. Bar graphs represent number of percentage of colonies formed 
with respect to vehicle control in each group. The experiments were performed in triplicate. Asterisk 
(*) denotes the significant value p < 0.05 when applied student’s t-test, and two asterisks (**) indicates 
as significance of p<0.01. 
3.2. Cuc D Treatment Effectively Arrests Cell Cycle in G2/M Phase 
Cancer progression is associated with the aberrant regulation of the cell cycle [26]. Thus, using 
PanCa cells, we investigated the effect of Cuc D on the cell cycle through flow cytometry. Cuc D 
caused a dose dependent growth arrest in the G2/M phase of the cell cycle (Figure 2Ai,ii; 
representative data for HPAF-II shown). The percentage of cells in the G2/M phase increased after 24 
h of drug treatment as compared to the vehicle control group, as shown in Figure 2A. 
 
Figure 2. Cuc D arrest cell cycle progression, decreases migration and invasion of pancreatic cancer
cells. (A) Effect of Cuc D on cell cycle distribution of HPAF-II cells as determined by flow cytometry.
Histogram represents the cell cycle distribution in control and Cuc D treated HPAF-II cells (Ai,Aii).
(B–D) Effect of Cuc D on cell migration of PanCa cells as determined by Boyden chamber assay (B),
agarose bead (C) and scratch wound (D). Representative images (magnification, × 20) of migratory
cells in control and Cuc D treated groups at 0 and 48 h (Bi). Bar graph represent the quantification
of migrated AsPC-1 cells of control and Cuc D treated groups (Bii). AB denotes agarose bead while
MC denotes migratory cells (C). Arrows indicate the distance of PanCa cells migration in control and
Cuc D treated groups (magnification, × 10). Scratch wound assay showing effect of Cuc D on HPAF-II
cells (D). Briefly, a standardized wound was made using a 200µL micropipette tip in 80–90% confluent
12-well plate and treated with indicated concentration of Cuc D. Closure of wound was determined
and photographed using phase contrast microscopy. Representative images (magnification, ×10) of
migratory cells in control and Cuc D treated groups at 0, 24 and 48 h. (E) Effect of Cuc D on invasion of
PanCa cells, as determined by a commercially available kit (BD Biosciences), as described in materials
and methods. Representative images (magnification, ×20) of invaded control and Cuc D treated cells
(Ei). Bar graph represent the quantification of invaded AsPC-1 cells of control and Cuc D treated groups
(Eii). Student’s t-test was performed to analyze significant difference. Asterisk (*) denotes significant
value p < 0.05.
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3.4. Cuc D Treatment Suppresses Invasiveness of PanCa Cells
The invasion of cancer cells is an integral process for cancer metastasis [27]. A matrigel invasion
assay was used to test the effect of Cuc D on the invasive ability of pancreatic cancer cells. As shown in
Figure 2E(i), Cuc D treatment significantly inhibited the invasiveness of pancreatic cancer cells starting
at 0.1 µM, invaded cells were counted and then plotted as a percentage of invasion of Cuc D treated
cells when compared to control (Figure 2E(ii)). These results suggest that Cuc D has potent anticancer
activity for reducing the invasiveness of PanCa cells.
3.5. Cuc D Treatment Inhibits MUC13 Expression in PanCa Cells
Previously, we reported the role of MUC13 as a diagnostic and therapeutic target in PanCa [19,20].
MUC13 mucin is aberrantly over-expressed in PanCa and the exogenous expression of MUC13 increases
tumorigenic features, such as enhanced cell proliferation, cell motility, cell invasion, and in vivo tumor
growth [19]. In the current study, we investigated the effect of Cuc D on MUC13 expression in PanCa
(AsPC-1 and HPAF-II) cells. As shown in Figure 3A(i,ii), treatment with Cuc D substantially reduced
MUC13 expression. We further observed that Cuc D treatment also decreases the mRNA level of
MUC13, as evidenced by qRT-PCR analysis (p < 0.05) (Figure 3B(i,ii)). It was found that 0.5 µM
Cuc D treatment down-regulates mRNA expression of MUC13 (Figure 3B(i,ii)). Previously, we have
shown that tumor suppressor miR-145 targets 3′ UTR of MUC13 and, thus, downregulates MUC13
protein expression in PanCa cells [20]. MicroRNA disruption has significant implications for PanCa’s
etiology, treatment, and pathogenesis. Thus, HPAF-II and AsPC-1 cells were treated with Cuc D, which
increased the expression of tumor suppressor miR-145 in PanCa cells, as determined by qRT-PCR
(Figure 3C(i,ii)). Furthermore, the PanCa cells were treated with Cuc D alone or in combination with
miR-145 inhibitor to investigate whether Cuc D restores tumor suppressor miR-145. Herein, treatment
with Cuc D decreased the levels of MUC13 and this decrease was partially reversed by the addition of
miR-145 inhibitor, as demonstrated by Western blot analysis (Figure 3D). These findings collectively
suggest that Cuc D significantly reduced MUC13 expression through the subsequent enhancement of
miR-145 expression in PanCa.
3.6. Molecular Docking Analysis
Molecular docking was used to envisage existing molecular interactions of Cuc D with amino
acid residues while utilizing Autodock, Autodock Vina™ combined with PyRx™ for workflow
management [21,28]. In case of MUC13, the selected domain was modeled and used for docking
studies. Figure 4A–C, Figures S1 and S2 present data from docking experiments. The results showed
that Cuc D forms stable complexes with MUC13 and binds deep into the binding cavity of protein
(Figure S1). The protein-ligand complexes were stabilized by several non-covalent interactions that
are offered by the residues present in the active site cavity of predicted MUC13 model (Figure 4A,B).
The results of docking revealed that Cuc D showed −7.6 kcal/mol binding energy for the MUC13
model (Figure 4C). Cuc D forms five hydrogen bonds with SER266(2), SER268, TYR237, and LEU263 of
selected MUC13 model. GLU230, GLU231, LYS232, HIS233, THR264, THR267, and LEU269 are the
other interacting residues (Figure 4B,C). These results suggested that Cuc D possesses high binding
affinity and forms stable complexes with MUC13. Re-docking the co-crystalized inhibitors of protein
into the active site cavity assessed the reliability of the applied docking protocol.
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3.7. Cuc D Treatment Induced Gemcitabine Sensitivity in Gemcitabine Resistant PanCa Cells
The current standard of care for metastatic pancreatic cancer is gemcitabine, but its success
is limited due to the emergence of drug resistance [29]. Therefore, we tested whether Cuc D has
anti-proliferative activity in gemcitabine-resistant AsPC-1 cells. Our data revealed a dose-dependent
inhibition in the proliferation of these cells (Figure 5A). We also determined the expression of MUC13 in
AsPC-1 cells that are resistant to gemcitabine. The expression of MUC13 decreases following treatment
with Cuc D treatment, as shown in Figure 5B,C(i). It has been reported that ribonucleotide reductase
(RRM1/2) have a direct role in the development of resistance [30]. Therefore, we observed the effect
of Cuc D on the expression of resistant markers RRM1 and RRM2 by qRT-PCR. The expression of
these markers with Cuc D treatment is significantly reduced, as shown in Figure 5C(ii,iii). The results
revealed that Cuc D inhibits the proliferation of cells that are resistant to gemcitabine.
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Figure 5. Effect of Cuc D on gemcitabine resistant AsPC-1 cells. (A) Briefly, 5000 cells were seeded in
96 well plate. Cells were treated with Cuc D at indicated concentrations for 48 h. Cell proliferation
was determined by MTS assay. Line graph indicates the percent viability of PanCa cells with respect
to vehicle control. Experi ent was performed in triplic te. (B) Effect of Cuc D treatment on MUC13
expression in gemcitabine resistant AsPC-1 cells as analyzed by semi quantitative PCR. (C) Cuc D
treatment decreases the mRNA expressions of MUC13 and drug resistant genes (RRM1 and RRM2)
as determined by qRT-PCR. GAPDH was used as an internal control (Ci–Ciii). Student’s t-test was
performed to analyze significant difference. Asterisk (*) denotes the significant value p < 0.05, and two
asterisks (**) indicates a significant level of p < 0.01.
3.8. Cuc D Effectively Inhibits Tumor Growth in NOD SCID Gamma (NSG) Xenograft Mouse Model
A xenograft mouse model was developed and then used to assess the effectiveness of Cuc D
to inhibit tumor growth in NSG mice. Following tumor development (~100 mm3), intra-peritoneal
injections of Cuc D (1 mg/kg body weight) and their respective vehicle control (PBS) were administered
to the mice for three days/week. The volumes and weight of the tumor were measured and presented
on the days that are shown in Figure 6A. At the end of the experiment, the mice were euthanized
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and, interestingly, Cuc D treatment showed an inhibition of tumor growth when compared to
their respective control groups (Figure 6A,B). The tumor tissue samples were further analyzed for
Immunohistochemistry (IHC) expression of MUC13 levels. Interestingly, in pancreatic xenograft
tumors, we found that Cuc D inhibited the expression of MUC13 (Figure 6C(i)). In addition, the
expression of PCNA (nuclear proliferating cell antigen) was also reduced (Figure 6C(ii)). In situ
miRNA-145 hybridization (ISH) in mice tumor tissues showed that Cuc D significantly increased the
expression of miRNA-145 when compared to their respective controls (Figure 6E). These in vivo data
further confirm the in vitro findings that Cuc D can decrease the levels of MUC13 to attenuate cell
growth (p < 0.05). Overall, our findings suggest that Cuc D has significant anti-tumor activity in the
xenograft pancreatic tumor model.
Cells 2019, 8, x 12 of 17 
 
 
Figure 6. Effect of Cuc D on growth of HPAF-II cells derived xenograft mouse model. (A) Line graph 
indicates regression of HPAF-II cell-derived xenograft tumor volume in Cuc D treated mice compared 
to control group. Values in bar graph represent mean ± SE of six mice tumors in each group. Asterisk 
(*) denotes the significant value p < 0.05. (B) Tumor weight of control and Cuc D treated mice. Asterisk 
(**) denotes the significant value p < 0.01. (C) Effects of Cuc D on the expression of MUC13 (Ci) and 
PCNA (Cii) in excised xenograft tumor tissues of control and Cuc D treated mice as determined by 
immunohistochemistry (D) Representative images were captured at 20× magnification. Bar graphs 
represent quantification of immunohistochemistry images of MUC13 (Di) and PCNA (Dii). Student’s 
t-test was performed to analyze significant difference. Asterisk (*) denotes the significant value 
p < 0.05. (E) The effect of Cuc D on the expression of miR-145 in control and treated mice excised 
tumors, as determined by in situ hybridization (magnification, ×20). (F) Pharmacokinetics studies of 
Cuc D (2 mg/kg bw) in mice by oral and i.p. route. 
3.9. Bioavailability of Cuc D in Mice 
2 mg/kg body weight was given to orally and intra-peritoneally to mice to evaluate the 
bioavailability of Cuc D in mice. We observed that single dose administration of Cuc D (2 mg/kg 
body weight orally) in NSG mice showed more serum concentration as compared to the i.p. 
administered group (Figure 6F). Furthermore, no toxicity was observed at this dose. 
4. Discussion 
Figure 6. Effect of Cuc D on growth of HPAF-II cells derived xenograft mouse model. (A) Line graph
indicates regression of HPAF-II cell-derived xenograft tumor volume in Cuc D treated mice compared
to control group. Values in bar graph represent mean± SE of six mice tumors in each group. Asterisk
(*) denotes the significant value p < 0.05. (B) Tumor weight of control and Cuc D treated mice. Asterisk
(**) denotes the significant value p< 0.01. (C) Effects of Cuc D on the expression of MUC13 (Ci) and
PCNA (Cii) in excised xenograft tumor tissues of control and Cuc D treated mice as determined by
immunohi tochemistry (D) Representa ive i ages were captured at 20×magnification. Bar graphs
represent quantification of immunohistochemistry images of MUC13 (Di) and PCNA (Dii). Student’s
t-test was performed to analyze significant difference. Asterisk (*) denotes the significant value p< 0.05.
(E) The effect of Cuc D on the expression of miR-145 in control and treated mice excised tumors, as
determined by in situ hybridization (magnification, ×20). (F) Pharmacokinetics studies of Cuc D
(2 mg/kg bw) in mice by oral and i.p. route.
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3.9. Bioavailability of Cuc D in Mice
2 mg/kg body weight was given to orally and intra-peritoneally to mice to evaluate the
bioavailability of Cuc D in mice. We observed that single dose administration of Cuc D (2 mg/kg body
weight orally) in NSG mice showed more serum concentration as compared to the i.p. administered
group (Figure 6F). Furthermore, no toxicity was observed at this dose.
4. Discussion
The PanCa management remains a major oncological challenge, as evidenced by the unchanged
overall survival [31]. Numerous emboldening approaches have been developed in targeted therapies
against PanCa, but the results in clinical tribulations are not encouraging. These limitations can
overcome by using complementary and alternative medicine approaches. Natural products that
are derived from plants have attracted wide attention because they are less toxic [32]. Several
studies have shown that Cuc D exhibit anticancer activity via multiple pathways in various cancer
models [13–17,33–38]. Song et al. (2013) have shown that Cuc D modulates the immune response
via the activation of inflammasome [35]. Interestingly, Ding et al. (2010) observed that Cuc D did
not show any toxicity in human peripheral blood lymphocytes form healthy donors [13]. There is
no report of therapeutic effect of Cuc D in PanCa, to the best of our knowledge. Therefore, in the
present study, we evaluated the anti-tumor effects of Cuc D in PanCa and attempted to investigate the
underlying mechanisms.
Our results show that Cuc D treatment inhibited the cell growth, suppressed the colony formation,
arrest cell cycle, and decreased the invasion and migration in PanCa cells. The schematic Figure 7
shows the overall effect of Cuc D on PanCa. Cuc D demonstrated a highly potent cytotoxic activity in
the nanomolar range against a panel of human PanCa cells (AsPC-1, BxPC-3, CaPan-1, and HPAF-II).
In line with our findings, Cuc D reportedly induced cell death in human T cell leukemia [14], breast
carcinoma [15], human endometrial and ovarian cancer cells [33], and cervical cancer [16].
We observed that Cuc D mediates the growth inhibitory effect on PanCa cells via arresting cells in
the cell cycle phase G2/M. G2 checkpoint has emerged as a captivating therapeutic target for cancer
therapy. These results are consistent with the other studies, where Cuc D induce cell cycle inhibition
in breast [15] and prostate [17] cancer cells. The importance of cell motility in tumor invasion makes
this an attractive target for therapeutics to inhibit metastatic PanCa. Our functional experiments
show that non-toxic Cuc D doses significantly decreased the PanCa cells migration and invasiveness.
Previously, we have shown that Cuc D effectively suppresses the invasiveness in cervical and prostate
cancer [16,17]. These findings suggest that Cuc D might be used to inhibit the metastasis of PanCa
cells. Interestingly, we found that treatment with Cuc D reduces the proliferation of PanCa cells that
are resistant to gemcitabine. Similarly, Cuc D treatment has been shown to overcome chemoresistance
in breast cancer cells [15].
Furthermore, the downregulation of MUC13 was one of the most important findings of our studies.
Mucins are identified as potential contributors to inflammation and cancer, hence they are considered
to be attractive tumor markers and they are attractive targets for therapy [39–41]. Previously, our
group has shown that MUC13 is highly upregulated in PanCa and a complex interplay of several
signaling pathways regulates its expression [19]. Continuing clinical studies draw attention for the
promise of mucins as therapeutic goals [42,43]. Several reports have shown the application of MUC1,
MUC2, MUC4, MUC5AC, and MUC16 for mucin based therapeutic approaches [42,43]. MUC13
targeting and down-regulation could be an important approach to novel drug therapies. We for the
first time provide evidence demonstrating that Cuc D can modulate mucin expression. This is in
accordance with other studies, where natural bioactive agents have shown to suppress PanCa growth
and down-regulate the mucin expression [44–46]. We further observed that the treatment with Cuc D
restored miR-145 expression, as seen by qPCR analysis in both HPAF-II and AsPC-1 cells. We also
noted that co-treatment with Cuc D and miR-145 inhibitor up-regulates the expression of MUC13, as
determined by Western blotting. These results revealed that Cuc D mediates the inhibition of MUC13
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in pancreatic cancer cells through miR-145 restoration. Nonetheless, further studies are required for
evaluating these basic parameters for gaining insight of Cuc D clinical benefits.
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Tumor xenograft study showed that pancreatic cancer cells that were derived from xenograft
tumors in mice were inhibited by the administration of Cuc D (1mg/kg body weight). No apparent
toxicity was observed in any of these mice. These results are consistent with other cucurbitacin analogs,
which also demonstrated the powerful anti- tumor activity in other cancers. Cuc D administration
showed a significant reduction (p< 0.05) in the expression of PCNA and MUC13 protein levels in excised
xenograft tumor tissues, further indicating that Cuc D has the potential to inhibit xenograft-derived
human pancreatic cancer cells. In situ hybridization analysis has shown that Cuc D has been effective
in restoring miR-145 expression. Overall, Cuc D has had a very promising effect on the growth of
pancreatic cancer and it could be a successful therapeutic strategy for PanCa.
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